# Deepak L. Bhatt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/deepak-l-bhatt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 224,661 |
| Field | Antiplatelet Therapy and Cardiovascular Diseases |
| h-index | 200 |
| i10-index | 1,641 |
| Last Known Institution | Clinical Research Institute |
| OpenAlex ID | https://openalex.org/A5010571732 |
| ORCID iD | 0000-0002-1278-6245 |
| Works | 3,613 |

## Researcher papers

Showing 12 of 65.

- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation](https://scholariq.org/papers/2020-esc-guidelines-for-the-management-of-acute-coronary-syndromes-in-patients/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](https://scholariq.org/papers/alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia](https://scholariq.org/papers/cardiovascular-risk-reduction-with-icosapent-ethyl-for-hypertriglyceridemia/)
- [Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes](https://scholariq.org/papers/bariatric-surgery-versus-intensive-medical-therapy-for-diabetes-5-year-outcomes/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events](https://scholariq.org/papers/clopidogrel-and-aspirin-versus-aspirin-alone-for-the-prevention-of/)
- [Guidelines for the Early Management of Adults With Ischemic Stroke](https://scholariq.org/papers/guidelines-for-the-early-management-of-adults-with-ischemic-stroke/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [A Controlled Trial of Renal Denervation for Resistant Hypertension](https://scholariq.org/papers/a-controlled-trial-of-renal-denervation-for-resistant-hypertension/)

## Researcher topics

- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Clinical Research Institute](https://scholariq.org/institutions/clinical-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.